Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148636 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
A Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by David Bushnell.
- Active
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06148636 is a Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2 that is active but no longer recruiting, run by David Bushnell. The registered enrollment target is 24 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06148636, a Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, is active but no longer recruiting, sponsored by David Bushnell.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
Conditions Studied
Interventions
- DRUG [212Pb] VMT-α-NET
- DIAGNOSTIC_TEST [203Pb] VMT-α-NET SPECT/CT
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center at the University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2027-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06148636
The ClinicalTrials.gov registry entry for NCT06148636 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (87% lower). The listed sponsor is David Bushnell, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which [212Pb] VMT-α-NET is the first listed.
NCT06148636 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06148636 about?
NCT06148636 is a clinical study titled "A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors". This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
What is the current status of trial NCT06148636?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-11-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06148636 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas.
What interventions are being tested in trial NCT06148636?
The interventions under investigation include: [212Pb] VMT-α-NET (DRUG), [203Pb] VMT-α-NET SPECT/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06148636?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06148636 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
ACTIVE NOT RECRUITING · Early Phase 1
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
COMPLETED · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.